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This study explored whether physical health problems are related to psychotic symptoms independently of a mental disorder diagnosis. A total
of 224,254 subjects recruited for the World Health Organization World Health Survey were subdivided into those with both a lifetime diagno-
sis of psychosis and at least one psychotic symptom in the 12 months prior to the evaluation, those with at least one psychotic symptom in the
past 12 months but no lifetime diagnosis of psychosis, and those without psychotic symptoms in the past 12 months and without a lifetime
diagnosis of psychosis. The three groups were compared for the presence of medical conditions, health problems, and access to health care.
Medical conditions and health problems (angina, asthma, arthritis, tuberculosis, vision or hearing problems, mouth/teeth problems, alcohol
consumption, smoking, and accidents), medication consumption, and hospital admissions (but not regular health care visits) were more fre-
quent in individuals with psychotic symptoms but no psychosis diagnosis, compared to those with no symptoms and no diagnosis. The number
of medical conditions increased with the number of psychotic symptoms. Given the sample analyzed, this trend seems to be independent from
the socio-economic development of the country or the specific health care system.
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Psychotic disorders have been associated with a mortal-
ity rate double that of the general population (1,2) and a
shortening of life expectancy by up to 20 years (3). Physi-
cal comorbidities are major contributors to morbidity and
mortality in people with schizophrenia and other psychot-
ic disorders (1,2,4-8). The impact of cardiovascular and
metabolic illnesses has been consistently reported (9-12),
and evidence is beginning to accumulate regarding the
role of infectious diseases, respiratory illness, and the abuse
of different substances, amongst others (1,7,12-16). Lifestyle
factors (such as sedentarism, inadequate diet and smoking),
treatment with antipsychotics, and unequal access to health
care have been suggested as contributors to poorer physical
health among people with psychosis (6,17-19). Immune
mechanisms and inflammation may also play a role, mediat-
ing not only the brain expression of the disorder, but also
the concurrent systemic problems (20).
Approximately 3% of the general population have a
psychotic disorder (21). However, the prevalence of psy-
chotic symptoms in population-based studies is signifi-
cantly higher, ranging from 0.7 to 45.8% for the presence
of at least one psychotic symptom in a recent world-wide
cross-national study (22). The negative impact of psychot-
ic symptoms on functioning seems not to be restricted to
individuals with diagnosable psychotic disorders (23,24).
Evidence regarding whether medical conditions and other
indices of physical health are related to the presence of psy-
chotic symptoms independently of an established mental
disorder diagnosis is still preliminary (25). Moreover, nearly
all of the available information regarding the larger than
expected comorbidity of physical illnesses with schizophre-
nia and other psychoses comes from studies conducted in
industrialized countries, mostly single-country studies (7,26).
In this paper, we present data from the World Health
Organization (WHO) World Health Survey (WHS), an
international study including countries with different levels
of socio-economic development (27). We explored the dif-
ferential load of physical illnesses and the access to treat-
ment for those illnesses in subjects presenting psychotic
symptoms (with or without a psychosis diagnosis) and sub-
jects without psychotic symptoms. We hypothesized that
the presence of psychotic symptoms (independent of a psy-
chosis diagnosis) would be related to medical pathology,
regardless of each country’s socio-economic level.
METHODS
Sample
We included individuals from the 52 countries covered
by the WHS: 18 from the African region, 13 from the
European region, 7 from the Americas region, 5 from the
Asian region, 5 from the South-East Asian region, and 4
from the Eastern Mediterranean region. Fifteen countries
were classified in the high or upper-middle economic levels,
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according to the World Bank, and 37 in the lower-middle or
low levels. All samples were drawn from a current national
frame using a multi-stage cluster design enabling each
household and individual respondent to be assigned a known
non-zero probability of selection. The sampling guidelines
and the summary descriptions of the sampling procedures are
available from the WHS website (www.who.int/healthinfo/
survey/en/index.html).
Informed consent was obtained from all respondents,
and the study was cleared by ethical review committees at
each site. The individual global response rate was 98.5%,
with the final sample comprising 224,254 subjects. All
interviews were conducted by specifically trained inter-
viewers. A standard procedure for training and quality
control was implemented at all sites and supervised peri-
odically, as per the specified guidelines.
Measures
All respondents were interviewed using the standard-
ized WHS instrument from the WHO. The interview
collected data on health status, socio-demographic char-
acteristics, consumption of alcohol and tobacco, lifestyle,
household economic status (based on a list of permanent
income indicators), and information about functioning,
health status and quality of life. Lifetime diagnosis and
treatment of psychosis and presence of psychotic symp-
toms during the last 12 months were assessed. Lifetime
diagnosis and symptoms during the last 12 months of
asthma, arthritis and angina pectoris were also recorded.
Alcohol consumption was coded using two groups and
one dummy variable, with lifetime abstainers and occa-
sional drinkers (those who consumed a total of 15 or less
units in the previous week, but no more than 4 units on
one occasion) being the reference category (87.4%), and
occasional heavy drinkers (those who consumed a total of
15 or more units in the previous week, but no more than 4
units on one occasion) and heavy drinkers (those who
consumed 5 or more units on at least one occasion) com-
prising the other category. Smoking was dichotomized as
not currently smoking any type of tobacco versus current-
ly smoking tobacco daily (23.8%).
Assessment of psychotic symptoms
Individual questions based on the WHS version of the
Composite International Diagnostic Interview (CIDI 3.0)
(28) were included to assess the presence of psychotic
symptoms, including delusional mood, delusions of refer-
ence and persecution, delusions of control, and hallucina-
tions, over the past 12 months. The response format for all
the above questions was dichotomous (yes/no). The psy-
chosis module of the CIDI has shown high concordance
with clinician ratings (29).
Assessment of specific medical conditions
The diagnosis of angina was based on an algorithm
derived from the Rose questionnaire (30). Asthma and
arthritis were established according to dichotomous ques-
tions (yes/no) about lifetime diagnosis of those illnesses
(31). Responders were regarded as having diabetes melli-
tus if they responded “yes” to the question “Have you ever
being diagnosed with diabetes (high blood sugar)?”. The
diagnosis of tuberculosis was established on the basis of
questions about a cough lasting more than three weeks
and including blood in cough or phlegm. Lifetime treat-
ment and medication use over the previous 2 weeks were
also assessed for all conditions.
The number of comorbid non-psychiatric illnesses, in-
cluding angina pectoris, asthma, diabetes, arthritis and tu-
berculosis, was assessed. Results about the association
between diabetes and psychotic symptoms in this sample
were already reported (32); therefore diabetes was only
considered to estimate the global amount of comorbid non-
psychiatric illnesses. Information was also included about
the self-reported presence (yes/no) of vision problems (and
of cataracts during the previous 5 years in people 60 years
and over), hearing problems, teeth problems, and road traf-
fic or other injuries in the 12 months before the interview.
Assessment of access to health care
Information about health system use and responsive-
ness was also collected. Occurrence and length of over-
night stays in health centers during the last 5 years, as well
as treatment at home or as an outpatient, were included in
the analyses, not considering stays potentially attributable
to psychiatric reasons. Satisfaction with health systems in
the country (from 1, very satisfied, to 5, very unsatisfied),
self-reported health dissatisfaction (from 1, very satisfied
to 5, very unsatisfied), and perceived lack of health (from
1, very good, to 5, very bad) were also assessed.
Medications being taken at the time of the interview
were reported. A total scale of number of medicines being
consumed was calculated (range: 0-6), excluding medica-
tion for psychiatric problems.
Statistical analysis
We first performed a series of binomial logistic regres-
sion analyses comparing subjects with a lifetime diagnosis
of psychosis and psychotic symptoms in the last 12 months
(N51,306) and subjects with at least one psychotic symptom
in the last 12 months but no psychotic diagnosis (N527,648)
vs. individuals without psychotic symptoms and no lifetime
diagnosis of psychosis (N5195,300). In all of these analyses
we statistically controlled for age, gender, World Bank cate-
gory of the country, and country of the individual (including
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51 dummy variables as covariates referred to the country of
the sample), the last two in order to control for potential dif-
ferences in the functioning of health services. Independent
variables included in those series of analyses were specific
medical conditions and access to health care.
Then, to test the global impact of psychotic symptoms
and diagnosis on health, we compared the total number of
non-psychiatric illnesses (including angina pectoris, arthri-
tis, asthma, diabetes and tuberculosis) and the consump-
tion of medicines prescribed by a medical professional
between individuals with lifetime psychotic diagnosis and
psychotic symptoms in the last 12 months and individuals
with at least one psychotic symptom and no diagnosis vs.
individuals without psychotic symptoms and no diagnosis
of psychosis.
Comparisons were performed through t-tests for unre-
lated samples, adjusting the probability level to control for
family-wise type I error (Bonferroni’s correction). To assess
the strength of these associations, effect sizes (Hedge’s g)
were calculated for associations with continuous variables.
Hedge’s g with large samples provides values that are very
similar to Cohen’s d (33), for which the following arbitrary
rules of thumb are often used: effect sizes below .20 are
regarded as not relevant, between .20 and .50 as low,
between .50 and .80 as moderate, and over .80 as high.
Also, with the aim of indirectly testing both overall health
and health-service responsiveness, the same comparisons
were carried out using the total number of medicines cur-
rently being taken (excluding those for psychiatric prob-
lems) as the dependent variable. Additionally, we analyzed
the differences in the number of illnesses and of medicines
currently being taken across the continuum of psychotic
symptoms (number of symptoms, range: 0-4) through one-
way ANOVAs, with the number of symptoms reported as
the independent variable and post-hoc comparisons (Scheffe)
between specific groups. Patients with a previous diagnosis
of psychosis and no psychotic symptoms in the past 12
months were not included in any analysis.
All analyses were carried out with the statistical pack-
age STATA, version 11.0 (Stata Corp, 2010). Significance
was set at a50.05.
RESULTS
In binary logistic regression analyses, all somatic varia-
bles considered had statistically significant ORs (p<0.001).
Thus, compared with subjects without psychotic symptoms
and no psychotic diagnoses, those with at least one psy-
chotic symptom in the last 12 months and no psychotic
diagnosis had a higher probability of also reporting angina
pectoris, asthma, arthritis, tuberculosis, vision or hearing
problems, cataracts (in people with 60 years or over), mouth
or teeth problems during the previous year, and high alcohol
consumption during the previous week, of being smokers,
and of having had more road accidents or other injuries in
the previous year (Table 1). The comparison of subjects with
psychotic symptoms and a diagnosis of psychosis vs. those
with no symptoms and no diagnosis produced very similar
results, although suggesting stronger associations. In fact,
comparing the two columns in Table 1, almost all 95% CIs
did not overlap (the only exceptions were those for cata-
racts, alcohol consumption and smoking), with a higher
range in the case of subjects with a diagnosis of psychosis.
As shown in Table 2, the presence of psychotic symp-
toms was related to an increased probability of health
Table 1 Physical diseases and health problems in subjects with psychotic symptoms and no psychotic diagnosis and in those with psy-
chotic symptoms plus lifetime psychotic diagnosis vs. subjects without psychotic symptoms or diagnosis
Psychotic symptoms
without psychosis
diagnosis OR (95% CI)
Psychotic symptoms
plus psychosis
diagnosis OR (95% CI)
Angina pectoris 2.50 (2.38/2.62) 3.98 (3.38/4.68)
Asthma 1.81 (1.72/1.91) 3.71 (3.16/4.75)
Arthritis 1.80 (1.73/1.86) 2.85 (2.50/3.25)
Tuberculosis 2.87 (2.66/3.11) 4.72 (3.73/5.97)
Vision problems 1.67 (1.59/1.75) 2.16 (1.80/2.58)
Cataracts (people over 60) 1.39 (1.24/1.57) 2.15 (1.28/3.61)
Hearing problems 1.56 (1.46/1.67) 2.27 (1.80/2.85)
Alcohol consumption (occasionally heavy/heavy) 1.27 (1.24/1.30) 1.14 (1.11/1.17)
Smoking (% currently yes) 1.18 (1.15/1.21) 1.30 (1.14/1.48)
Mouth or teeth problems (last year) 1.63 (1.58/1.67) 2.06 (1.83/2.32)
Road traffic or other injuries (1 year) 2.34 (2.23/2.44) 3.21 (2.72/3.79)
All results are significant compared to individuals without diagnosis of psychosis nor psychotic symptoms in the prior 12 months
Values in bold indicate non-overlapping 95% CIs between the two columns
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dissatisfaction, worse self-rated health, higher dissatis-
faction with health care in the country, and higher self-
reported consumption in the two previous weeks of medi-
cines for most conditions included in the study, except for
HIV. There was also a statistically significant positive
effect for at least one overnight stay in hospital during the
previous five years (excluding psychiatric reasons), and for
the length of the stay. Comparing people with psychotic
symptoms and a lifetime diagnosis of psychosis vs. those
without diagnosis and symptoms, there was also an
increased probability of most variables in the former, except
for consumption of medicines for HIV or asthma, as well as
for the length of the last overnight stay in a hospital for non-
psychiatric reasons.
Comparing the two columns in Table 2, there was an
overlap in ORs, except for hospital stay in the previous 5
years, consumption of medicines for angina, health dissat-
isfaction, self-reported lack of health, and total number of
medicines currently being taken, for which the presence of
diagnosis plus psychotic symptoms in the last 12 months
was associated with a higher probability.
The mean number of somatic illnesses was significantly
higher (t534.0; p<0.001; g51.05, 95% CI: 0.99-1.11) in
subjects with a psychotic diagnosis and psychotic symptoms
(0.7960.97) than in those with no psychotic symptoms or
diagnosis (0.2460.52). Similarly, it was significantly higher
(t5 57.8; p<0.001; g50.40, 95% CI: 0.39-0.41) in individu-
als with at least one psychotic symptom but no psychotic
diagnosis (0.4660.72) than in those without diagnosis or
symptoms. Among subjects with psychotic symptoms, the
Table 2 Health system care indicators in subjects with psychotic symptoms and no psychotic diagnosis and in those with psychotic
symptoms plus lifetime psychotic diagnosis vs. subjects without psychotic symptoms or diagnosis
Psychotic symptoms
without psychosis
diagnosis OR (95% CI)
Psychotic symptoms
plus psychosis
diagnosis OR (95% CI)
Overnight stays (excluding psychiatric) 1.33 (1.28/1.38)a 1.91 (1.65/2.22)
Length of stay (excluding psychiatric)
3-5 days 1.15 (1.07/1.25)a 1.34 (0.99/2.22)
6-14 days 1.22 (1.11/1.34)a 1.41 (1.00/1.99)a
More than 15 days 1.37 (1.22/1.54)a 1.45 (0.94/2.22)
Health care attention, excluding overnight and psychiatric (12 months) 1.79 (0.69/4.62) 0.67 (0.09/4.97)
Health dissatisfaction 1.28 (1.26/1.29)a 1.51 (1.44/1.60)a
Self-rated lack of health 1.42 (1.41/1.44)a 1.77 (1.69/1.86)a
Dissatisfaction with health care in country 1.12 (1.11/1.13)a 1.11 (1.05/1.16)a
Prescribed medicines used last two weeks
Arthritis 1.63 (1.49/1.79)a 1.94 (1.36/2.76)a
Angina pectoris 1.30 (1.15/1.47)a 2.43 (1.65/3.59)a
Asthma 1.20 (1.03/1.39)a 1.44 (0.80/2.57)
Tuberculosis 1.86 (1.29/2.69)a 3.75 (1.37/10.29)a
HIV/AIDS 1.10 (0.66/1.83) 2.95 (0.87/10.03)
Other (non-psychiatric) 1.41 (1.35/1.48)a 1.64 (1.36/1.99)a
Total medicines (0–6) 1.31 (1.26/1.35)a 1.54 (1.36/1.75)a
aSignificant results using as comparison group individuals without diagnosis of psychosis nor psychotic symptoms in the prior 12 months
Values in bold indicate non-overlapping 95% CIs between the two columns
Figure 1 Linear prediction of number of illnesses according to the
number of psychotic symptoms, with 95% confidence bands. Illnesses
included: angina pectoris, arthritis, asthma, diabetes, and tuberculosis
(range 0-5).
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association with somatic illnesses was stronger in subjects
with a lifetime diagnosis of psychosis than in those without,
as shown by the not overlapping CIs in the effect sizes.
As shown in Figure 1, the number of somatic illnesses
increased with the number of reported psychotic symptoms
(F5969.3; p<0.001). Post-hoc comparisons (Scheffe) indi-
cated that people reporting four psychotic symptoms had
significantly more somatic illnesses (0.6860.88) than the
other groups (p<0.001 in all comparisons); people with
three symptoms (0.5260.78) had more illnesses (p<0.001)
than people with two (0.4560.71), one (0.4060.66) or zero
(0.2460.52) symptoms; people with two symptoms had
more illnesses (p<0.001) than those with one or no symp-
toms; and people reporting one symptom had more illnesses
than those without symptoms and no lifetime diagnosis of
psychosis (p<0.001).
Individuals with psychotic symptoms in the past 12 months
and a lifetime diagnosis of psychosis had consumed more
medicines prescribed by a medical professional (excluding
psychiatric medications) than persons without psychotic
symptoms or diagnosis (0.1960.48 vs. 0.1460.41, t54.1;
p<0.001). Likewise, people with at least one psychotic
symptom tookmore medicines than those without symptoms
or diagnosis (0.1660.43 vs. 0.1460.41, t57.8, p<0.001).
When comparing the amount of medicines consumed by
subjects with different numbers of reported psychotic symp-
toms, there was a clear overall omnibus difference (F518.1,
p<0.001). However, post-hoc comparisons (Scheffe) indicat-
ed that differences were only in the direction of a higher con-
sumption for those with one (0.1760.44; p50.012), or two
(0.1760.44; p50.021) as compared to persons with four psy-
chotic symptoms (0.1460.40), and with one, two or three
symptoms (0.1660.41; p<0.001 in all comparisons) as com-
pared to those without psychotic symptoms (0.1460.41).
DISCUSSION
The presence of even isolated psychotic symptoms may
confer risk for medical comorbidities. Our results indicate
that individuals with psychotic symptoms but no psychot-
ic diagnosis, compared to those without psychotic diagno-
sis or symptoms, present more lifetime medical conditions
and health problems, more (and longer) non-psychiatric
overnight stays in hospital (with no differences in other
health care indicators), and higher consumption of non-
psychiatric medicines prescribed by a professional. Most
results are replicated, and in most comparisons the effects
are higher, when subjects with a diagnosis of psychosis
plus psychotic symptoms over the last 12 months are
included in the analyses.
Although our results are in line with previous work sug-
gesting that psychotic illnesses are related with worse
physical health (4,5,7,8,34) and higher rates of various
medical conditions such as angina pectoris or cardiovas-
cular problems (10-12,35), asthma or pulmonary prob-
lems (13,35-37) and tuberculosis (38,39), they suggest that
this relationship is not dependent on the presence of a
psychotic disorder, but that the critical factor is having
experienced at least one psychotic symptom. The same
applies to the association of psychotic symptoms with
other health-related factors, such as presence of acci-
dents, including automobile accidents (40), mouth or teeth
problems (7,13,41,42), smoking (4,10-12,18), alcohol abuse
(4,5,43) or hearing and vision problems (13,44,45). Although
a lower frequency of rheumatoid arthritis has been previously
reported for patients with schizophrenia (7,46), this negative
association was not replicated in a population-based analysis
(47), which also found that the incidence of arthritis in
parents of schizophrenia patients was higher than in parents
of controls. Unlike most previous studies on psychosis, the
term arthritis in this study was not restricted to rheumatoid
arthritis. A positive relationship between schizophrenia and
rheumatic diseases has also been found previously (47,48).
The use of health care services was higher in persons
with psychotic symptoms, particularly in cases with more
severe problems needing inpatient attention. Regular visits
to health services, however, were not more common among
subjects with psychotic symptoms. A possible explanation
for this finding could be that patients with psychotic symp-
toms have worse access to the usual filter systems, given
their pathology-driven difficulties in engaging in routine
medical care and interpreting illness-related signs (49,50).
To be identified by the health system, somatic illnesses in
individuals with psychosis may need to be more severe, or
to have progressed enough to require treatment in hospital
settings (51). Self-rated lack of health and dissatisfaction
with health, higher in people with vs. without psychotic
symptoms in our sample, also point in that direction.
In all analyses, country of origin, gender, age, and socio-
economic status were statistically controlled for. Therefore,
it can be assumed that the results of the present study are
globally independent of the country, the socio-economic
status or the development level of health systems in each
country.
The higher frequency of medical conditions among peo-
ple with psychoses in this international sample replicates
previous results from single countries, but the finding that
similar medical complications are present among subjects
with isolated psychotic symptoms regardless of their coun-
try of origin, has not been, to our knowledge, previously
reported, and points to a greater disadvantage of these indi-
viduals, even if they are not to develop a full psychotic ill-
ness or if they are in the earlier stages of psychotic pro-
cesses. Our results may be explained by the existence of a
physiopathological link based on genetic, inflammatory,
immunological and/or metabolic mechanisms, underlying
the relationship between psychotic symptoms and physical
diseases (20,52-54). The higher frequency of smoking and
excessive alcohol consumption, found in our study among
subjects with psychotic symptoms, could also mediate the
association between those symptoms and physical diseases.
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Promoting general physical health and improving screening
methods for comorbid medical conditions (55-58) seems
to be relevant in persons with psychotic symptoms across
countries, even if they do not meet criteria for a psychotic
disorder.
The cross-sectional nature of this study does not make it
possible to address the direction of the causal link between
medical conditions and psychotic symptoms. Likewise, the
lack of data on potential determinants of severity or disabil-
ity associated with psychotic symptoms, such as the num-
ber and frequency of episodes, episode length, age at onset,
and episode severity, limits the generalization of results to
the whole continuum of persons with psychotic symptoms.
In addition, the range of psychotic experiences was limited,
and not assessed by a clinical interview. Longitudinal stud-
ies with more experienced interviewers are needed in order
to analyze the natural history of these symptoms in the gen-
eral population (59).
The strengths of the study include the large sample size
and the worldwide scope, including all regions of the world
with all levels of development. Most of the research in the
domain of psychotic experiences has been conducted in
Western countries, and little is known about regions in
which multiple economic, cultural or social factors or dif-
ferences in the health systems can markedly affect the dis-
tribution of psychotic symptoms. The present study was
performed with nationally representative samples of non-
institutionalized persons, avoiding potential problems asso-
ciated with clinical samples, such as Berkson’s bias (60).
Notably, country effects, including the categorization of the
country’s economic status (in addition to individual age
and gender), were statistically controlled for.
In conclusion, the present study shows that the presence
of at least one psychotic symptom, independent of a psy-
chotic disorder diagnosis, is related to more comorbid med-
ical problems, risky lifestyle behaviours, and an increased
use of health services for chronic medical conditions,
involving overnight stays in hospitals. Given the sample
analyzed, this trend seems to hold worldwide, regardless of
the socio-economic development of the country or the spe-
cific health care system. Patients with psychotic disorders
and even with psychotic symptoms not fulfilling diagnostic
criteria for a psychotic disorder should be screened for
additional medical problems, and general practitioners
should be trained in the identification of patients with these
problems, in order to optimize the functioning of health
systems and avoid the problems and additional costs asso-
ciated with comorbid conditions.
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